This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers’ ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

(Reuters) -Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1. The one-time price will also be available through ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm's weight-loss drug, Wegovy.

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...

Novo Nordisk ( ($NVO) ) has risen by 10.44%. Read on to learn why. Novo Nordisk has seen a notable 10.44% increase in its stock price over the ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.